Development and Preclinical Evaluation of a Dual-Drug Implant for Long-Acting HIV Prevention and Contraception
A single-rod subcutaneous implant releasing islatravir and etonogestrel was well tolerated in rabbits and released both drugs steadily over about 90 days, although islatravir levels were below HIV-prevention targets.
August 2026
Click for full info +Multipurpose prevention technologies (MPTs) that combine protection against HIV and unintended pregnancy can improve women’s health outcomes by simplifying use and enhancing adherence. We developed a long-acting (LA) implant for the simultaneous and sustained delivery of the antiretroviral islatravir (ISL) and the contraceptive hormone etonogestrel (ENG).
Full Info:
Resource Type:
Journal Article
Journal Article
Resource
Authors: Krovi, A., Levin, L., Gatto, G.J., Luecke, E.H., Brand, R., Swistok, A., Cottrell, M.L., Schauer, A.P., Johnson, L.M.
Health Risks(s):
- HIV
- Unintended Pregnancy
Product type(s):
- ARVs
- Hormonal
- Implants
- MPTs
Topic(s):
- MPTs
- Development
Region(s)
- United States
Additional Keywords:
implant; islatravir; etonogestrel; preclinical
URL of resource: